Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $42.13 Average Target Price from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $42.13.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Chardan Capital reissued a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 14th.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This trade represents a 1.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 275,880 shares of company stock valued at $4,034,037 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its position in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,628 shares during the last quarter. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $38,000. GF Fund Management CO. LTD. bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $49,000. Van ECK Associates Corp lifted its position in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares during the last quarter. Finally, CWM LLC lifted its position in shares of Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,523 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $15.71 on Friday. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $30.41. The firm has a fifty day moving average of $13.30 and a 200-day moving average of $17.78. The firm has a market capitalization of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same period in the previous year, the company earned ($1.02) EPS. As a group, analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.